HCG vs kisspeptin for fertility: what the evidence shows

What did @therestoreclinic actually say?

The creator argued that for men on testosterone replacement therapy, HCG is the better adjunct compared to kisspeptin-10. The reasoning: kisspeptin-10 works upstream, stimulating the hypothalamus to release GnRH, which then drives FSH and LH, which then tell the testes to function. HCG, by contrast, acts directly on the Leydig cells. The creator claimed kisspeptin-10 "does not have a large robust response in testosterone production," peaks in 30-40 minutes, returns to baseline in about 180 minutes, and requires daily dosing. HCG, with a half-life of roughly 24 hours, wins on convenience and also supports upstream hormones like pregnenolone, which the creator called "the principal hormone at the top of the hormonal cascade."

The mechanism walkthrough here is mostly accurate at a textbook level. The conclusion favoring HCG is defensible, though presented with more certainty than the current clinical literature actually supports.

Does the science back this up?

The core pharmacology is largely correct, but the evidence comparing these two agents head-to-head in TRT-adjacent contexts is thin. The kisspeptin-10 half-life figure is roughly consistent with published data. George et al. (2012, Clinical Endocrinology) confirmed that IV kisspeptin-10 produces a short-lived LH pulse with a plasma half-life under 30 minutes, and testosterone responses are modest and transient. That part checks out.

The claim that HCG has a half-life of roughly 24 hours is a simplification. HCG has a biphasic half-life. The alpha phase is approximately 6 hours; the beta phase is closer to 24 hours. Citing only the 24-hour figure is not wrong, but it is incomplete.

The pregnenolone claim is real but overstated. HCG does stimulate steroidogenesis upstream of testosterone, and Stocco and Clark (1996, Endocrine Reviews) established that LH receptor activation in Leydig cells drives the full steroidogenic cascade. Whether this meaningfully alters pregnenolone levels at typical TRT adjunct doses in humans is not well-established in controlled trials.

What did they get wrong (or right)?

The creator got the directional mechanism mostly right. Kisspeptin-10 does work upstream via the HPG axis, and HCG does bypass it to act directly on Leydig cells. That distinction is real and clinically relevant. Credit for that.

What is less accurate is the claim about tolerance. The creator says tolerance "is likely with both" but is "more likely with KISS PEPTIN-10, given its very short half-life." This is speculative. The evidence on kisspeptin tachyphylaxis in humans comes primarily from studies using continuous or very frequent infusions, not the subcutaneous injection protocols used in practice. Skorupskaite et al. (2014, Human Reproduction Update) reviewed kisspeptin desensitization and noted it is dose-regime-dependent, not simply a consequence of short half-life.

The creator also mispronounced "Leydig" as "lading" and "Sertoli" as "sertolese." These are minor, but for a health education channel these errors matter. Sertoli cells support spermatogenesis; they are not directly stimulated by LH. The creator's claim that testosterone from Leydig cells then "stimulates the neighboring Sertoli cells to produce sperm" is an oversimplification. Sertoli cells require both FSH and intratesticular testosterone to support spermatogenesis, and FSH has a distinct, non-redundant role that HCG monotherapy does not fully replicate.

What should you actually know?

The practical conclusion here is defensible but not the whole picture. HCG is a well-established adjunct to TRT for men who want to preserve testicular volume and fertility potential. Coviello et al. (2005, Journal of Clinical Endocrinology and Metabolism) demonstrated that low-dose HCG maintains intratesticular testosterone during exogenous T administration. That is solid, replicated evidence.

Kisspeptin-10 as a TRT adjunct is still largely experimental in clinical practice. Most human data comes from research settings studying its role in fertility and GnRH pulse generation, not from controlled trials comparing it to HCG as an add-on for TRT patients. The creator is essentially comparing an established clinical tool to an emerging one and concluding the established one is better. That conclusion may be correct for right now, but framing kisspeptin-10 as simply inferior misses that research is ongoing and its role may evolve.

Neither agent is a treatment for any disease. Anyone considering adjunct therapy alongside TRT should be evaluated by a licensed prescriber who can review their individual lab values, fertility goals, and health history.